Research graph
References from SGLT2 versus DPP-4 inhibitors in type 2 diabetes: a meta-analysis of outcomes. Local targets link to admitted publications; unresolved targets remain external evidence.
Global risk factors, epidemiology, and disease burden of type 2 diabetes
10.1007/s11427-024-3036-4 · 2026 · External reference
A systematic review of the economic burden of diabetes mellitus: contrasting perspectives from high and low middle-income countries
10.1080/20523211.2024.2322107 · 2024 · External reference
Heterogeneity of cardiovascular effects of second-line glucose-lowering therapies in adults with type 2 diabetes across the range of moderate baseline cardiovascular risk
10.1161/jaha.124.040217 · 2025 · External reference
Comparative effectiveness of second-line antihyperglycemic agents for cardiovascular outcomes: a multinational, federated analysis of LEGEND-T2DM
10.1016/j.jacc.2024.05.069 · 2024 · External reference
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
10.1038/s41569-020-0406-8 · 2020 · External reference
Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus
10.1038/s41574-020-0399-8 · 2020 · External reference
SGLT-2 inhibitors and DPP-4 inhibitors as second-line drugs in patients with type 2 diabetes: a meta-analysis of randomized clinical trials
10.1055/a-0733-7919 · 2018 · External reference
Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis
10.7326/m15-2650 · 2016 · External reference
Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes
10.1002/14651858.cd015588.pub2 · 2024 · External reference
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement
10.1186/2046-4053-4-1 · 2015 · External reference
Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin
10.2337/dc14-2364 · 2015 · External reference
Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial
10.1016/s2213-8587(22)00387-4 · 2023 · External reference
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
10.1007/s00125-013-3039-1 · 2013 · External reference
Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes
10.2337/dc14-2365 · 2015 · External reference
Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: the VERTIS FACTORIAL randomized trial
10.1111/dom.13194 · 2018 · External reference
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
10.1016/s2213-8587(13)70084-6 · 2013 · External reference
Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes
10.2337/dc11-1926 · 2012 · External reference
Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia
10.1111/dom.12185 · 2013 · External reference
Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial
10.2337/dc12-2491 · 2013 · External reference
A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: the CompoSIT-R study
10.1111/dom.13473 · 2018 · External reference
Model-based meta-analysis of HbA1c reduction across SGLT2 inhibitors using dose adjusted by urinary glucose excretion
10.1038/s41598-024-76256-6 · 2024 · External reference
Association between daily dose of dipeptidyl peptidase-4 inhibitors and change in glycated hemoglobin in patients with type 2 diabetes: interpretation of mixed-effects machine-learning models using electronic medical records
10.1186/s40360-025-01055-2 · 2025 · External reference
Cardiometabolic and renal benefits of sodium-glucose cotransporter 2 inhibitors
10.1038/s41574-025-01170-4 · 2025 · External reference
GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials
10.3389/fendo.2020.00178 · 2020 · External reference
A hypothesis for why sodium glucose co-transporter 2 inhibitors have been found to cause genital infection, but not urinary tract infection
10.1111/dom.13959 · 2020 · External reference
Risk of urogenital bacterial infection with sodium-glucose cotransporter-2 inhibitors: a retrospective cohort study using a claims database
10.1007/s13300-024-01613-7 · 2024 · External reference
